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ABSTRACT 
Objectives: Many patients with osteoarthritis have comorbid symptoms of fibromyalgia (FM), 
but it unknown how these symptoms respond to surgical procedures that address nociceptive 
input in the periphery, such as total joint replacement. Here we explore differences in clinical 
characteristics between patients whose FM symptoms do and do not improve following total 
hip or knee replacement. 
Methods: Participants were 150 patients undergoing knee or hip replacement who had a 
minimum FM survey score of 4 or greater prior to surgery. The top tertile of patients 
experiencing the most improvement in FM symptoms at month 6 were categorized as ‘Improve’ 
(n=48) while the bottom two tertiles were categorized as ‘Worsen/Same’ (n=102). .  Baseline 
symptom characteristics were compared between groups, as well as improvement in overall 
pain severity, surgical pain severity and physical function at six months.  
Results: The Worsen/Same group had higher levels of fatigue, depression, and surgical site pain 
at baseline (all p < 0.05).  Additionally, they improved less on overall pain severity and physical 
functioning six months after surgery (both p < 0.05).  
Conclusion: Most patients derive significant benefit in improvement of comorbid FM symptoms 
following total joint replacement, but a substantial proportion do not.  Understanding the 
neurobiological basis for these different trajectories may help inform clinical judgment and 
improve patient care. 
Keywords: Osteoarthritis; Fibromyalgia; total joint replacement; central sensitization 
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Key messages:  
• Most patients with osteoarthritis experience substantial improvement in comorbid 
fibromyalgia symptoms after total joint replacement. 
• A minority of patients with osteoarthritis regress to pre-surgical levels of fibromyalgia 
symptoms by month six. 
• Osteoarthritis patients who show less benefit have higher levels of fatigue and 
depression before the procedure. 
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INTRODUCTION 
It is now widely accepted that the symptoms used to define fibromyalgia (FM), such as 
widespread pain, fatigue, and cognitive dysfunction, are present to some degree in all 
rheumatic disorders and chronic pain conditions.[1]  The level of these symptoms, or the 
degree of FM symptoms an individual possesses are hypothesized to be associated with 
aberrant central nervous system mechanisms.  This hypothesis is supported by imaging 
techniques designed to explore the brain’s structure, function, and neurochemical features.[2-
4]   It was recently demonstrated that the degree of FM symptoms (measured on a continuum 
via the 2011 FM Survey Criteria[5]) in rheumatoid arthritis (RA) correlates with increased 
connectivity between the insula and Default Mode Network of the brain [6], replicating one of 
the most salient neurobiological findings in clinical FM populations[7].  These central 
differences may be why the degree of FM symptoms a patient has prior to surgery is a strong 
predictor of post-surgical outcomes such as the likelihood of improvement in pain and need for 
analgesics.[8-11]    
It has been hypothesized that comorbid FM symptoms in other rheumatologic conditions may 
arise through two relatively distinct pathways: ‘bottom up’ and ‘top down’ mechanisms of 
central sensitization.[12]  ‘Top down’ mechanisms of central sensitization refer to pain 
amplification that exists independent of peripheral inflammation and other nociceptive input.  
This concept is supported by the frequent disagreement between the degree of damage or 
inflammation in the joint and the severity of symptoms reported by the patient.[13]  These ‘top 
down’ mechanisms are believed to be familial and to disproportionately affect females [14, 15].  
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In an osteoarthritis (OA) patient whose comorbid FM symptoms are driven primarily by ‘top 
down’ mechanisms surgery should have limited benefit for pain outside the surgical site. 
Conversely, in some patients, peripheral sources of nociceptive input such as joint inflammation 
and damage sensitize the CNS to pain in a ‘bottom up’ fashion.  According to this view, chronic 
injury and/or inflammation, such as that due to OA, drives central nervous system sensitization, 
resulting in comorbid FM symptoms. Woolf originally advanced the term ‘central sensitization’ 
to describe this process when spinal and brain mechanisms promote pain at sites distal from 
the primary injury, damage, or inflammation, a phenomenon well established in animal 
models.[13]  In a patient where comorbid FM symptoms are being driven by chronic 
nociceptive input in the knee or hip, arthroplasty should improve these symptoms by reducing 
the source of central sensitization.  In fact, a reduction in global pain sensitivity does seem to 
occur in a subset of individuals receiving lower extremity arthroplasty.[14]    
Examining how comorbid FM symptoms change after lower extremity arthroplasty, where the 
primary source of nociceptive input is removed, allows for a natural experiment to identify 
phenotypes consistent with ‘bottom up’ versus ‘top down’ mechanisms.  Using a cohort of OA 
patients undergoing hip and knee arthroplasty, we sought to identify different patterns of how 
FM symptoms change following the procedure, as well as the baseline characteristics 
associated with these patterns.  We also sought to determine if there were marked differences 
in the temporal pattern of these changes, and if these patterns were associated with different 
clinical outcomes following surgery. 
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METHODS 
Sample 
The eligible pool of participants were 453 individuals undergoing either knee or hip 
replacement surgery at Michigan Medicine.  These patients were recruited between April, 2015 
and November, 2016.  The current study was approved by the University of Michigan 
Institutional Review Board and all participants provided informed consent. Of these, 107 were 
using opioid medications prior to surgery, which may influence the comorbid symptoms of 
interest from the 2011 Fibromyalgia Survey Criteria, and were therefore excluded from further 
analyses.  A comparison of symptoms between patients taking/not taking opioids at baseline is 
shown in Supplementary Table S1, available at Rheumatology online.  Analyses were restricted 
to participants showing at least moderate levels of comorbid symptoms prior to surgery as 
indicated by a 4 or greater on the 2011 criteria; participants with scores below 4, the sample 
median of patients not taking opioids at baseline, were excluded.  Of the remaining 201 
participants, 51 did not have data available at the follow up visit (month 6) and were also 
excluded.  This resulted in a final sample of 150 participants.  Demographic information is 
shown in Table 1.   
Measures 
The 2011 survey criteria for FM was used to assess widespread body pain and comorbid 
symptoms.[5]  The 2011 criteria contains a 19 areas that can be indicated as painful, and 
several questions about constitutional symptoms such as fatigue, cognitive difficulties, and 
unrefreshing sleep.  These aspects of the centralized pain spectrum can be analyzed separately 
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as the Widespread Pain Index (WPI) and Symptom Severity Index (SSI).  The SSI serves as an 
index of somatic and constitutional symptoms that are frequently present in FM.  A more 
detailed body map (the Michigan Body Map [MBM][15] ) containing 35 sites was administered 
that includes all the WPI sites, allowing us to calculate the WPI.  A non-surgical site pain index 
was created by removing the bilateral surgical sites from the respective cohorts (hips from the 
hip cohort, knees from the knee cohort) -- this allows us to examine the impact of the 
procedure on pain outside the surgical site.  Overall pain severity, and surgical site pain 
severity, was measured by the Brief Pain Inventory (BPI)[16].  The Patient-Reported Outcomes 
Measurement Information System-Short Forms (PROMIS®-SF) were used to measure 
depression, anxiety, fatigue, sleep disturbance, and physical function. [17].  Six questions from 
the catastrophizing subscale from the Coping Strategies Questionnaire (CSQ) were used to 
measure catastrophic cognitive appraisal of pain[18].  Primary outcomes for baseline analyses 
were FM survey criteria (WPI and SSI), depression, fatigue, and sleep disturbance.  For 
longitudinal analyses the primary outcomes were change scores in physical function, overall 
pain severity, and surgical site pain severity.  Age, sex, and surgical cohort were examined as 
potential confounding variables. 
Group Definitions 
To identify groups that showed different patterns of comorbid symptom change after surgery, 
we first calculated a simple change score between baseline and month 6 for the 2011 FM 
survey criteria.  We then regressed this change score on the baseline survey score to account 
for regression to the mean type effects.  The resulting residuals were divided into three tertiles 
by rank values.  We compared the proportion of each group who achieved at least a 30% 
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reduction in FM symptoms by month 6 using Chi-square tests, or Fisher’s exact test when 
expected counts are less than 5, with correction for multiple comparisons.  We subsequently 
combined the top two tertiles into one group (n=102), ‘Improve,’ for comparison to the bottom 
tertile, ‘Worsen/Same.’ 
Statistical Analyses 
Baseline comparisons 
Improve versus worsen/same comparisons were made on continuous outcomes by t-test and 
categorical outcomes by chi-square statistic.  Primary outcomes for baseline analyses were FM 
survey criteria (overall, WPI, and SSI), depression, fatigue, and sleep disturbance.  Additionally, 
anxiety, MBM non-surgical sites, non-surgical and surgical pain severity, as well as age, were 
compared between groups. Surgical site (hip versus knee), and gender were categorical 
outcomes.  We also compared those patients who were included in the study (with available 
six-month data; n=150) to those who were lost to follow-up (n=48), on age, gender, surgical site 
and baseline levels of FM symptoms. 
Longitudinal analyses 
Trajectory of change 
The trajectory of change in total 2011 FM Survey Scores, MBM non-surgical site pain (e.g. not 
surgical hip or knee), and SSI scores were examined in mixed-effect models, with random 
subject-specific intercept and time effects, using restricted estimation of maximum likelihood.  
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Both linear and quadratic effects of time were modeled and the primary outcomes of interest 
were grouped by time interaction terms.   
Improvement in non-surgical pain and physical function 
Primary outcomes were change scores in BPI overall pain severity and PROMIS physical function 
measures (pre-surgery – month 6 scores).  These change scores were then compared between 
groups in general linear models controlling for baseline scores, participant age, and surgical 
group. 
Surgical-site pain after surgery 
The primary outcomes was surgical pain (yes/no) was compared between groups at each post-
surgical time point, week 2, month 1, month 3, and month 6, by chi-square test. 
RESULTS 
Group Definitions 
A very small proportion of those patients in the lowest tertile of FM improvement achieved a 
30% reduction in FM symptoms (6.3%).  Conversely, 89% of those in the middle tertile, and 
100% of those in the top tertile achieved 30% improvement.  The difference between low and 
middle tertiles was significant (Chi-square = 68.5; p <.001) as was the difference between low 
and high tertiles (Chi-square = 85.7; p < .001).  However, there was no statistically significant 
difference in the proportion of those showing 30% improvement between the middle and high 
tertiles (Fisher’s exact adjusted p = .08).  These top two tertiles were subsequently combined, 
as mentioned above.   
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Baseline Comparison 
Age, gender, and surgical cohort did not differ significantly between the groups (all p > 0.13; 
See Table 1).  Similarly, there were no significant pre-surgical group differences on painful body 
sites measured by the WPI or non-surgical sites on the MBM, the SSI, sleep disturbance, 
physical function, pain catastrophizing, or overall pain severity (all p > 0.10).  Conversely, total 
FM survey scores (p = 0.045), fatigue (p= 0.014), depression (p = 0.003), and surgical site pain 
severity (p = 0.032) were elevated in the Worsen/Same group compared to those who 
improved (See Table 1 for means and SDs by group for each measure).   
Those patients who did not have complete six-month data were younger than those who did 
(mean loss to follow-up = 56.02; SD= 14.33; 95% CI = 51.86, 60.18; mean included = 63.01; SD= 
10.08; 95% CI= 61.39, 64.64; p < .001).  There were no significant differences in baseline FM 
symptoms (mean loss to follow-up = 7.29; SD= 2.86; 95% CI = 6.46, 8.12; mean included =7.03; 
SD= 2.66; 95% CI= 6.60, 7.46; p =.57).  There were no differences in the proportion of each 
group having hip replacement (loss to follow-up = 47.9%; included = 56.7%; p = .29) or in the 
proportion of female patients (loss to follow-up = 56.3%; included = 61.3%; p = .53). 
 
Longitudinal Analyses 
Trajectory of change 
The effect of time on total FM scores differed substantially by group (time by group interaction, 
p < 0.001).  The change over time in MBM non-surgical pain sites (excluding the hip or knee) 
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and SSI scores also differed by group (time by group interaction, both p < 0.001) indicating that 
both comorbid pain and constitutional symptoms contribute to the different trajectories in 
total score improvement (See Figure 1 for group trajectories and change in pain distribution 
over time).  In both groups, improvement occurred at the one-month time point, but by month 
three, the Worsen/Same group showed substantial regression in their symptoms, such that by 
month six they had returned to pre-surgical levels of FM symptoms.  Conversely, the Improve 
group continued to show benefits at month three and through month six.  These non-linear 
patterns are reflected in the greater deviation from linear change seen in the Worsen/Same 
group for total FM survey and SSI scores (quadratic effect of time by group interaction, both p < 
0.05).  All model output is shown in Table 2.  MBM non-surgical pain and SSI trajectories are 
shown in Supplementary Figure S1, available at Rheumatology online.  
Improvement in non-surgical pain and physical function 
Participants in the Worsen/Same group showed significantly lower levels of improvement in 
overall pain severity at month 6, after controlling for baseline symptom levels, age, and surgical 
site (p=.004).  The estimated improvement in overall pain severity for the Improve group was 
2.25 points (95% CI= 1.84, 2.65; S.E.=0.20) or 48% of pre-surgical levels, versus 1.21 points (95% 
CI= .63, 1.79; S.E. = 0.29) or 25% or pre-surgical levels for the worsen/same group.  Similarly, 
the Worsen/Same group showed significantly less improvement in physical function (p= 0.021).  
The estimated improvement in physical function for the Improve group was 5.66 (95% CI= 2.95, 
5.17; S.E.=0.39) or 43% of pre-surgical levels, versus 4.06 (95% CI= 4.89, 6.43; S.E. = 0.56) or 
29% of pre-surgical levels for the Worsen/Same group..  In analyses where patients still taking 
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opioid medications after month 1 were removed, (Worsen/Same n=6 [12.5%], Improve n=4 
[3.9%]), the results were similar (data not shown).   
Improvement in surgical-site pain. 
At month 6, there was no difference in the percentage of participants reporting no surgical-site 
pain (yes/no) between the two groups (Improve = 74%, Worsen/Same = 69%, χ2=.37; df=1, p = 
0.54).  Conversely, at week 2 (Improve = 27%, Worsen/Same = 9%, χ2=5.92; df=1, p = 0.015), 
month 1 (Improve = 43%, Worsen/Same = 13%, χ2=12.99; df=1, p < 0.001), and month 3 
(Improve = 73%, Worsen/Same = 54%, χ2=4.71; df=1, p = 0.030), a smaller proportion of 
participants in the Worsen/Same group reported being pain free at the surgical site.  See Figure 
2.   
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DISCUSSION 
These analyses show that the trajectory of change in FM symptoms after joint replacement 
surgery follow distinct patterns.  In most patients, significant improvement in FM symptoms, 
including multifocal pain and constitutional symptoms, occurs rapidly (i.e. one month) and is 
maintained through six months following the procedure. The observed improvement in both 
constitutional symptoms and widespread pain is important as it indicates that this phenomenon 
is not simply due to improved referred pain or biomechanics following the procedure.  
Conversely, approximately one third of patients demonstrate a relatively modest improvement 
in these symptoms at one month, followed by a reversion to pre-surgical levels by month six, 
despite improvement in pain at the surgical site.  This means that for a subset of OA patients, 
no long-term benefit for comorbid highly burdensome symptoms like multifocal pain, fatigue, 
and sleep disruption can be expected, as neither non-surgical site pain or constitutional 
symptoms improved for the vast majority of this subgroup.  These different effects are not due 
to pre-surgical levels of comorbid FM symptoms, which were controlled for in our analyses.  
These phenotypes are consistent with divergent mechanisms in how comorbid symptoms are 
generated.   In a recent series of reviews exploring the neurobiological evidence for central 
sensitization, Woolf and others advanced two hypothetical subtypes: ‘bottom-up’ and ‘top-
down’ central sensitization.[12] [19] For most patients, with what can be called ‘bottom-up’ 
sensitization, the removal of the primary nociceptive generator reduces FM symptoms, perhaps 
by attenuating central sensitization.  For a substantial minority of patients – the ‘top-down’ 
phenotype -- the procedure has no long-term benefit for comorbid FM symptoms.  Clearly, 
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these novel distinctions need to be explored further, but in our view they provide a helpful 
framework for exploring the variability in how OA patients respond to total joint replacement. 
There are several important implications of these findings for both the mechanistic 
understanding of central sensitization in patients undergoing joint replacement procedures and 
for their clinical care. These findings are foreshadowed to some degree by the neglected 
concepts of primary and secondary fibromyalgia.[20, 21]  In a majority of patients comorbid FM 
symptoms respond favorably to surgery, suggesting that these symptoms were driven or 
maintained by nociceptive input in the affected joint.  This finding is supported by a previous 
study indicating that successful OA surgery results in substantial improvement of responses to 
experimental pain measures outside the surgical site; patients whose surgery eliminated their 
pain showed a more normal inhibitory response to evoked pain than they did prior to surgery 
[14].  Animal models have demonstrated convincingly that regional and even widespread 
hyperalgesia follow localized chronic injury or inflammation such as sciatic constriction or 
repeated formalin injections – an analog to ‘bottom-up’ sensitization[22] and we have recently 
shown that peripheral inflammation is associated with profound changes in brain function in RA 
that promote core symptoms of FM [23].  Together these findings suggest that bottom-up 
mechanisms are important in rheumatic diseases. 
Comparing the locations of pain improvement/non-improvement following surgery shows that 
in the Improve group, the largest effects are seen the lower body contiguous with or near the 
site of surgery, with some additional benefits for back pain. Conversely, the Worsen/Same 
group of patients do not show these effects.  These patients showed modest improvement in 
the lower body, and an overall pattern of worsening in the upper extremities.  This is consistent 
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with some animal models of fibromyalgia wherein removal of nociceptive input in the periphery 
has no effect on global hyperalgesia once the animal becomes centrally sensitized [24].  
Patients in the Worsen/Same group showed worsening of comorbid symptoms at the same 
time that surgical-site pain seemed to resolve, in contrast with those in the Improve group 
whose comorbid symptoms and surgical-site pain improved in tandem.  Surgical site pain 
seemed to persist for longer in a larger proportion of patients in the Worsen/Same group.  This 
suggests that the distinction between peripherally driven central-sensitization, and centrally 
maintained central-sensitization, is in fact an important one. 
The Worsen/Same group of patients showed substantially less improvement in both overall 
pain severity and functional disability six months after the procedure.  This may simply reflect 
the fact that their comorbid symptoms have not improved, despite comparable levels of 
surgical-site improvement to the Improve group.  Nonetheless, these metrics represent 
important benchmarks for improvement following joint-replacement.  Because surgical site 
pain improved equally in the two groups, it could fairly be said that a good deal of the overall 
improvement observed in the Improve group is due to improvement in comorbid symptoms 
(e.g. fatigue, trouble thinking/remembering), rather than surgical site pain.  Clinically, this 
means that monitoring improvement in symptoms outside the surgical site is important, and 
should be done in tandem with questions about the severity of pain in the surgical area.  It is 
also critical to monitor these symptoms beyond the first month post-operatively, as both 
groups appeared to improve at one month, a time when substantial numbers of patients in 
both groups were still using narcotic analgesics.  Furthermore, the difference between patient 
groups in those reporting surgical site pain was no longer apparent at six months, this suggests 
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that longer (i.e., at least six months) follow-up may be necessary to identify patients who failed 
to respond to the procedure in terms of surgical site pain. 
These findings raise the critical question of how patient phenotypes might be distinguished 
prior to surgery.  Our analyses were designed to control for pre-surgical levels of fibromyalgia 
symptoms, so that the trajectory of improvement could be isolated from regression to the 
mean type effects.  Nonetheless, pre-surgical symptom levels revealed higher levels of fatigue, 
depression, and surgical site pain severity in the Worsen/Same group.  These differences were 
modest and do not appear to lend themselves to forming reliable cutoffs (effect sizes range 
from 0.35- 0.51).   
There are many ways in which these two different subsets of arthroplasty patients might be 
better differentiated prior to surgery, that we did not measure in this study.  For example, 
individuals with a ‘top-down’ form of FM that is most commonly studied in mechanistic studies 
have high rates of co-morbid chronic overlapping pain conditions (COPCs) that typically present 
earlier in life.[25, 26]  Individuals with FM similarly have been repeatedly shown to have much 
higher rates of mood disorders[27], again supportive of a primary brain mechanism, rather than 
a peripherally-driven phenomenon. We and others have also shown that individuals with the 
primary form of FM that occurs without obvious evidence of ongoing nociceptive input display 
evidence of not only pain sensitivity, but are also much more sensitive to the intensity and 
unpleasantness of other sensory modalities, such as light and sound, and that this is a critical 
feature that can correctly classify individuals with FM vs. those without on functional 
neuroimaging studies.[28-31]   
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These findings point to the further need for mechanistic studies that explore the 
neurobiological substrates of patients who show these different trajectories in improvement 
following conventional peripherally-directed treatments.  The clinical impact of better 
understanding these two subsets is obvious, since the bottom-up subset should benefit from 
aggressive use of peripherally-directed therapies, including not only appropriate surgery or 
injections, but also the use of drugs such as the Nerve Growth Factor antibodies that may soon 
become available, and might be able to eliminate ongoing nociceptive input better than any 
currently available therapies.[32, 33]     
Limitations 
We chose our cutoff for inclusion (minimum score of 4) using the distribution of the FM scores 
in the sample, this decision was still somewhat arbitrary as there are no subclinical cutoffs on 
the FM survey instrument to define moderate symptoms.  Additionally, the loss of 
approximately 25% of the patient sample at six months represents a potential source of bias.  
While included patients did not differ on baseline FM symptoms, they were older on average 
than those lost to follow-up, and therefore these patterns will need to be confirmed in younger 
patients.  No information was collected about the duration of symptoms for either OA or FM, 
and consequently we cannot define secondary FM in the current sample.  The group definitions 
used here were derived retrospectively and led to differences in subgroup sizes.  Future studies 
may employ a matched design. 
Patients undergoing knee and hip replacement show distinct trajectories in how FM symptoms 
improve, or do not improve, after the procedure.  Improvement in comorbid FM symptoms 
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appears to occur in a substantial number of patients undergoing arthroplasty.  These 
trajectories are related to the overall impact of the procedure on measures of pain and 
disability after six months.  These differences are not readily apparent in symptom phenotyping 
performed prior to the procedure, but may be revealed through mechanistic phenotyping using 
neuroimaging and quantitative sensory testing.  Future studies will determine if and how these 
patterns hold in other surgical cohorts with high levels of comorbid FM symptoms. 
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Figure Legends 
Figure 1. Smoothed group trajectories of the 2011 FM Survey Score following surgery.  
Individual trajectories are shown in light gray.  Colors on the body map correspond to 
percentage changes in each group showing improvement in each region.  Regions are adapted 
from the regional pain definitions of the 2016 Fibromyalgia Survey criteria. Shaded regions 
show 95% confidence intervals. 
Figure 2.  Smoothed trajectories showing the probability of surgical pain from pre-surgery to 
month 6.  Significant differences at week 2, month1, and month 3 are shown with p values.  
Individual data points are shown as triangles.  Shaded regions show 95% confidence intervals. 
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Table 1.  Demographic and symptom information at baseline for Worsen/Same and Improve 
groups. 
 
Worsen/S
ame  Improve  
t df p 
 
Mean 
(95% CI) SD 
Mean 
(95% CI) SD 
   
age 
61.75 
(58.98, 
64.52) 
9.5
4 
63.61 
(61.58, 
65.63) 
10.
31 
-
1.0
54 
14
8 
.29
4 
Widespread Pain Index (0-19)  
2.75 
(2.18, 
3.32) 
1.9
5 
2.40 
(2.06, 
2.74) 
1.7
4 
1.1
00 
14
8 
0.2
73 
Michigan Body Map non-
surgical sites   
3.83 
(2.89, 
4.78) 
3.2
6 
3.66 
(3.08, 
4.23) 
2.9
3 
0.3
32 
14
8 
0.7
41 
Symptom Severity Index 
4.92 
(4.32, 
5.52) 
2.0
7 
4.33 
(3.94, 
4.73) 
2.0
3 
1.6
33 
14
8 
0.1
05 
FM Survey Score 
7.67 
(6.82, 
8.51) 
2.9
3 
6.74 
(6.25, 
7.22) 
2.4
9 
2.0
20 
14
8 
0.0
45 
Fatigue 
11.88 
(10.97, 
12.78) 
3.1
1 
10.36 
(9.65, 
11.07) 
3.6
1 
2.4
99 
14
8 
0.0
14 
Depression 
6.96 
(6.07, 
7.84) 
2.9
9 
5.57 
(5.11, 
6.04) 
2.3
7 
3.0
13 
14
5 
0.0
03 
Sleep Disturbance 
26.91 
(25.04, 
28.79) 
6.3
9 
26.45 
(25.14, 
27.76) 
6.5
7 
0.3
99 
14
4 
0.6
90 
Physical Function 
13.98 
(13.04, 
14.92) 
3.2
5 
13.09 
(12.45, 
13.73) 
3.2
3 
1.5
71 
14
7 
0.1
18 
Pain Catastrophizing  
5.46 
(3.62, 
7.30) 
6.1
9 
4.00 
(3.07, 
4.93) 
4.6
8 
1.5
71 
14
4 
0.1
18 
Brief Pain Inventory Pain 
Severity (Overall) 
4.85 
(4.13, 
5.58)  
2.4
9 
4.72 
(4.19, 
5.25) 
2.7
0 
0.2
90 
14
8 
0.7
72 
Pain Severity (Surgical Site) 
6.90 
(6.39, 
7.40) 
1.7
5 
6.23 
(5.88, 
6.58) 
1.7
6 
2.1
62 
14
8 
0.0
32 
 
frequency 
(%) 
 frequency 
(%) 
 χ2  p 
23 
 
FM positive  
2 (4)  3 (3)  .15
2 
 .65
5a 
Gender (Female) 
33 (69)  59 (58)  1.6
37 
1 .20
1 
Surgical cohort (knee) 
25 (52)  40 (39)  2.2
0 
1 .13
8 
 
a Fisher’s Exact Test.   
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Table 2.  Fixed effects for models of change in FM total scores, non-surgical pain, and 
symptom severity index.   
 
The quadratic time variable was centered 
 
Variable Estimate S.E. DF t  p 
FM total scores 
Intercept 5.997 1.055 173.4 5.685 < .001 
Time -0.016 0.141 369.5 -0.114 0.910 
Time2 1.071 0.159 426.5 6.756 < .001 
Age -0.011 0.016 147 -0.675 0.501 
Surgical Cohort (hip) -0.250 0.317 148 -0.787 0.432 
Group (Improve) -0.018 0.514 239 -0.034 0.973 
Time X Group -1.432 0.170 369.1 -8.402 < .001 
Time2 X Group -0.394 0.192 426.1 -2.059 0.040 
non-surgical site pain 
Intercept 3.283 0.993 179.1 3.306 0.001 
Time -0.065 0.171 149.3 -0.377 0.706 
Time2 0.547 0.159 280.96 3.442 0.001 
Age -0.017 0.014 145.51 -1.177 0.241 
Surgical Cohort (hip) 0.586 0.296 146.59 1.983 0.049 
Group (Improve) -0.195 0.513 225 -0.381 0.704 
Time X Group -0.810 0.207 149.02 -3.908 < .001 
Time2 X Group -0.008 0.192 280.54 -0.044 0.965 
Symptom Severity Index 
Intercept 3.881 0.818 169.1 4.746 < .001 
Time 0.149 0.101 385.4 1.468 0.143 
Time2 0.699 0.114 427.6 6.109 < .001 
Age -0.004 0.012 146.4 -0.328 0.743 
Surgical Cohort (hip) -0.571 0.248 147.3 -2.307 0.022 
Group (Improve) 0.284 0.383 234.5 0.743 0.458 
Time X Group -1.035 0.123 385.1 -8.441 < .001 
Time2 X Group -0.369 0.138 427.3 -2.671 0.008 
